News Headlines

  1. LenioBio And Twist Bioscience Enter Into A Collaboration To Further Enable AI Drug-Discovery 5/8/2026

    LenioBio GmbH, a TechBio company commercializing its ALiCE cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation.

  2. 3PBIOVIAN Strengthens Its End-To-End CDMO Offering With State-Of-The-Art Sterility Testing, From Clinical To Commercial 5/7/2026

    3PBIOVIAN has significantly strengthened its sterility testing capabilities, reinforcing its position as an integrated, end-to-end CDMO serving biopharma customers from early development through commercial supply.

  3. Halozyme Announces Global Collaboration And License Agreement With GSK To Develop Subcutaneous Formulations Of Multiple Promising Oncology Targets 5/7/2026

    Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license agreement with GSK.

  4. SK pharmteco Collaborates With Axle Informatics And The National Institutes Of Health To Advance Rare Disease Gene Therapy Programs 5/7/2026

    SK pharmteco today announced a strategic partnership with Axle Informatics and the National Institutes of Health (NIH) to advance the development of gene therapies for rare diseases.

  5. Bristol Myers Squibb Licenses Antibody-Drug Conjugate Technology From Lonza 5/7/2026

    Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), and Bristol Myers Squibb, a global pharmaceutical company dedicated to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases, today announced an exclusive single-target licensing agreement.

  6. Halozyme And Oruka Announce Global Collaboration And License Agreement To Develop ORKA-001 With Hypercon Technology 5/6/2026

    Halozyme Therapeutics, Inc. (“Halozyme”) and Oruka Therapeutics, Inc. (“Oruka”) today announced that Halozyme’s wholly owned subsidiary, Halozyme Hypercon, Inc., has entered into a global exclusive collaboration and license agreement with Oruka.

  7. Neuland Secures Development Collaboration With LIR Life Sciences For Transdermal GLP-1 5/6/2026

    Neuland Laboratories Limited, a global contract development and manufacturing organisation (CDMO) specialising in complex APIs, has entered into a development partnership with LIR Life Sciences Corp, a Canada-based biotechnology company focused on scalable and accessible obesity treatments, in advancing its cell-penetrating peptide (CPP) platform.

  8. Tissue Dynamics And Galmed Pharmaceuticals To Develop Human-Centered Chronic Cardiac Fibrosis Platform To Advance Aramchol-Based Therapeutics 5/6/2026

    Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a collaboration to develop a novel human chronic cardiac fibrosis model designed to accelerate the discovery and development of new Aramchol-based therapeutic approaches for complex fibrotic heart diseases.

  9. BioOra Limited And Wellington Zhaotai Therapies Limited (WZTL) Sign Heads Of Terms To Advance Their Global Expansion Of CAR T-Cell Therapy 5/6/2026

    BioOra Limited, a New Zealand-based company pioneering automated, cost-effective CAR T-cell manufacturing, today announced the signing of a binding Heads of Terms agreement with Wellington Zhaotai Therapies Limited (Wellington Zhaotai) under which BioOra secures global rights to develop and commercialise Wellington Zhaotai's novel third-generation anti-CD19 CAR T-cell therapy for the treatment of multiple conditions (WZTL-002), including haematological malignancies and auto-immune diseases.

  10. Hongene Demonstrates Advanced Oligonucleotide CDMO Capabilities Through Support Of SiranBio's Dual-Target siRNA Program 5/5/2026

    Hongene Biotech Corporation today announced its support of SiranBio’s SA1211 program, a dual-target siRNA candidate for chronic hepatitis B, underscoring Hongene’s ability to deliver end-to-end development and manufacturing solutions for structurally complex oligonucleotide therapeutics.